<DOC>
	<DOCNO>NCT02287467</DOCNO>
	<brief_summary>Influenza ( flu ) common illness usually occur autumn winter . The flu usually mild , cause serious illness death . The purpose study test safety effectiveness antibody flu ( call intravenous hyperimmune immunoglobulin IVIG ) people hospitalize severe flu .</brief_summary>
	<brief_title>Evaluating Safety Efficacy Anti-Influenza Intravenous Hyperimmune Immunoglobulin ( IVIG ) Adults Hospitalized With Influenza</brief_title>
	<detailed_description>Influenza responsible thousand hospitalization death year United States worldwide . One possible new treatment flu involve use IVIG , blood product contain antibody people recover flu flu shot . The purpose study evaluate whether IVIG reduce severity duration flu people hospitalize flu . The study enroll participant 18 year old hospitalize flu . The study enroll participant one flu season . Regardless date enrollment , participant study 28 day . At study entry ( Day 0 ) , participant randomly assign one two group ( Arms A B ) . Participants group receive standard care ( SOC ) treatment flu , Arm A also receive one dose IVIG Arm B receive placebo IVIG . Both IVIG placebo give intravenously least 2 hour . On Day 0 , receive IVIG placebo , participant undergo symptoms assessment , blood collection , nasopharyngeal ( NP ) swab collect sample secretion nose throat . Additional study visit occur Days 1 , 2 , 3 , 7 , 14 , 28 . Depending visit , participant may take part study procedure take place Day 0 . On Days 2 , 14 , 28 , visit participant longer hospitalize may conduct phone .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Signed informed consent Locally determine positive influenza test ( polymerase chain reaction [ PCR ] nucleic acid test , rapid antigen [ Ag ] ) specimen obtain within 2 day prior randomization Onset illness 7 day randomization , define participant first experience least one respiratory symptom fever Hospitalized ( observation unit ) influenza , anticipate hospitalization 24 hour . Criteria hospitalization individual treat clinician . For woman childbearing potential : willingness abstain sexual intercourse use least one form hormonal barrier contraception Day 28 study Willingness blood respiratory sample obtain store NEW score great equal 2 screening ( see protocol information criterion ) Women pregnant breastfeeding Strong clinical evidence ( judgment site investigator ) etiology illness primarily bacterial origin Prior treatment investigational drug therapy within 30 day prior screen History allergic reaction blood plasma product ( judge site investigator ) Known immunoglobulin A ( IgA ) deficiency A preexisting condition use medication , opinion site investigator , may place participant substantially increase risk thrombosis ( e.g. , cryoglobulinemia , severe refractory hypertriglyceridemia , clinically significant monoclonal gammopathy ) Presence preexist illness , opinion site investigator , would place participant unreasonably increase risk participation study Participants , judgment site investigator , unlikely comply requirement protocol Medical condition receipt 500 mL volume intravenous fluid may dangerous participant ( e.g. , decompensated congestive heart failure ) Receiving extracorporeal membrane oxygenation ( ECMO ) Suspicion infection due influenza strain subtype A ( H1N1 ) pdm09 , H3N2 , influenza B ( e.g. , H5N1 , H7N9 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Antiviral</keyword>
	<keyword>IVIG</keyword>
	<keyword>Hemagglutination inhibition ( HAI )</keyword>
	<keyword>Antibody</keyword>
</DOC>